POZZI, Samantha
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.464
EU - Europa 4.840
AS - Asia 3.720
SA - Sud America 607
AF - Africa 124
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 7
Totale 20.791
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.341
GB - Regno Unito 2.042
CN - Cina 1.218
SG - Singapore 1.057
IT - Italia 719
HK - Hong Kong 573
DE - Germania 491
BR - Brasile 485
SE - Svezia 449
UA - Ucraina 229
VN - Vietnam 223
RU - Federazione Russa 220
FR - Francia 168
TR - Turchia 158
FI - Finlandia 154
IN - India 93
BG - Bulgaria 85
ID - Indonesia 83
KR - Corea 81
CA - Canada 75
IE - Irlanda 50
MA - Marocco 50
AR - Argentina 48
JP - Giappone 46
NL - Olanda 37
BE - Belgio 26
MX - Messico 26
ES - Italia 25
PL - Polonia 25
LT - Lituania 23
ZA - Sudafrica 23
BD - Bangladesh 21
IQ - Iraq 21
PH - Filippine 21
AU - Australia 20
CZ - Repubblica Ceca 19
MY - Malesia 19
CL - Cile 16
PK - Pakistan 14
CO - Colombia 13
EC - Ecuador 13
IR - Iran 13
AT - Austria 12
NO - Norvegia 12
PY - Paraguay 12
CH - Svizzera 11
EG - Egitto 11
SA - Arabia Saudita 10
TW - Taiwan 9
NZ - Nuova Zelanda 8
RO - Romania 8
UZ - Uzbekistan 8
AE - Emirati Arabi Uniti 7
BZ - Belize 7
KE - Kenya 7
KG - Kirghizistan 7
PT - Portogallo 7
UY - Uruguay 7
VE - Venezuela 7
GH - Ghana 6
HU - Ungheria 6
IL - Israele 6
GR - Grecia 5
TZ - Tanzania 5
AZ - Azerbaigian 4
DO - Repubblica Dominicana 4
EU - Europa 4
JO - Giordania 4
KH - Cambogia 4
NG - Nigeria 4
PE - Perù 4
GP - Guadalupe 3
KZ - Kazakistan 3
LB - Libano 3
MD - Moldavia 3
TN - Tunisia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BO - Bolivia 2
CR - Costa Rica 2
DK - Danimarca 2
DZ - Algeria 2
ET - Etiopia 2
LV - Lettonia 2
MK - Macedonia 2
OM - Oman 2
SN - Senegal 2
SV - El Salvador 2
TH - Thailandia 2
UG - Uganda 2
AD - Andorra 1
BF - Burkina Faso 1
CY - Cipro 1
GT - Guatemala 1
HR - Croazia 1
IS - Islanda 1
Totale 20.776
Salva come PNG Salva come JPEG
Città #
Southend 1.620
Fairfield 1.270
Santa Clara 1.125
Ashburn 1.053
Woodbridge 828
Singapore 699
Chandler 644
Houston 622
Hong Kong 569
Ann Arbor 487
Seattle 466
Wilmington 455
Cambridge 450
Jacksonville 417
Dearborn 320
Nyköping 307
Beijing 299
Hefei 291
London 255
Chicago 193
Modena 178
Los Angeles 172
New York 160
San Diego 130
Frankfurt am Main 129
Princeton 96
Ho Chi Minh City 87
Salt Lake City 85
Sofia 84
The Dalles 83
Izmir 80
Eugene 79
Moscow 74
Shanghai 74
Munich 73
Seoul 70
Helsinki 65
Council Bluffs 60
Jakarta 60
Buffalo 54
Rome 54
Hanoi 53
Dublin 48
Bremen 46
São Paulo 46
Casablanca 43
Milan 43
Redwood City 42
Elk Grove Village 38
Falls Church 38
Des Moines 36
Columbus 33
Fremont 33
Phoenix 33
Dallas 32
San Giuliano Milanese 28
Tokyo 27
Guangzhou 24
Tampa 24
Turku 24
Boardman 23
Warsaw 23
Brussels 21
Norwalk 21
Montreal 20
Lancaster 19
Dong Ket 18
Sterling 18
Denver 17
Nanjing 17
Toronto 17
Belo Horizonte 15
Bologna 15
Brooklyn 15
Chennai 15
Parma 15
San Francisco 15
Stockholm 15
Nuremberg 14
Ottawa 14
San Jose 14
Miami 13
Redondo Beach 13
Amsterdam 12
Atlanta 12
Johannesburg 12
Orem 12
Rio de Janeiro 12
San Mateo 12
Tappahannock 12
Boston 11
Buenos Aires 11
Chengdu 11
Poplar 11
Brno 10
Detroit 10
Jinan 10
Kunming 10
Paris 10
Philadelphia 10
Totale 15.583
Salva come PNG Salva come JPEG
Nome #
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 581
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 515
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 471
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 449
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 441
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 398
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 380
The undergraduate nursing student evaluation of clinical learning environment: an Italian survey [La valutazione dell'ambiente di apprendimento clinico da parte degli studenti del Corso di Laurea in Infermieristica: una indagine italiana] 367
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 353
Cell-penetrating CaCO3nanocrystals for improved transport of NVP-BEZ235 across membrane barrier in T-cell lymphoma 350
Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) 349
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 341
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 332
Activity of BKM120 and BEZ235 against lymphoma cells 326
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 324
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 319
Acquired haemophilia in HIV negative, HHV-8 positive multicentric Castleman's disease: a case report 318
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 310
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 299
A concise review of lenalidomide therapy for follicular lymphoma 291
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 290
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 288
Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery 284
Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphy et al 280
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 271
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 262
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 261
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection 259
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 255
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 254
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 246
Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases 246
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 244
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 240
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts 240
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 239
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. 237
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 236
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 232
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 231
Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy. 230
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma 229
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 227
The potential of pralatrexate as a treatment of peripheral T-cell lymphoma 225
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 220
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) InfectionBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3054 218
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells 214
A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. 213
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease 212
Low-molecular-weight heparin for vertebral artery dissection 210
Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL. 207
A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of Multiple Myeloma 204
Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time 204
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 201
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 195
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts 193
The therapeutic strategy of HDAC6 inhibitors in lymphoproliferative disease 191
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma 187
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination 186
Diffuse B-large cell lymphomas with hepatitis C virus (HCV) infection: An interim report of a comparative study with or without antiviral treatment after chemotherapy 183
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo 182
Bortezomib and plasma cell leukemia 181
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 179
The role of bisphosphonates in multiple myeloma: Mechanisms, side effects, and the future 177
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 176
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. 175
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting 169
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. 168
Antiviral treatment with interferon +/- ribavirin after chemotherapy for diffuse large B-cell non-Hodgkin lymphomas with hepatitis C virus (HCV) infection 168
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice 166
Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma 159
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. 158
Role of thalidomide in previously untreated patients with multiple myeloma 157
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED FOLLICULAR LYMPHOMAS: LOW TOXICITY AND EXTENDED PROGRESSION FREE SURVIVAL. R1235 Barcelona, Spain. Bone Marrow Transplantation March 2004, Volume 33, Supplement 1 147
Bisphosphonates and Atypical Femoral Fractures 146
AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3 beta 142
The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis 140
Fatty acid synthase is a novel therapeutic target in multiple myeloma. 133
A simple and safe nomogram for the management of oral anticoagulation prior to minor surgery 131
Clinicopathological, cytogenetic, and molecular profiles of primary cutaneous diffuse large B-cell lymphomas 123
Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity 114
Clinical trials of bisphosphonates in multiple myeloma 106
From Osteoclast Differentiation to Osteonecrosis of the Jaw: Molecular and Clinical Insights 96
Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature 93
Management of adverse events and supportive therapy in relapsed/refractory multiple myeloma 87
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study 86
Autologous stem cell transplantation for newly diagnosed follicular lymphomas: low toxicity and extended progression free survival 83
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3Β activation and RNA polymerase II inhibition 80
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study 80
Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study) 76
Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: Pathophysiology, clinical presentation, and treatment 71
Primary cardiac lymphoma: A case report and review 52
Totale 20.959
Salva come PNG Salva come JPEG
Categoria #
all - tutte 81.539
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.539
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.406 0 0 0 0 0 166 168 266 142 279 241 144
2021/20221.758 77 166 203 63 40 153 100 95 193 148 314 206
2022/20231.821 197 221 163 192 189 263 44 157 250 14 79 52
2023/20241.410 74 77 70 155 322 98 200 160 23 32 70 129
2024/20253.793 123 50 88 270 819 610 288 195 398 171 332 449
2025/20263.662 431 297 563 962 1.221 188 0 0 0 0 0 0
Totale 20.959